Toward drugs derived from cannabis.
Recent work aimed at the introduction of natural and synthetic cannabinoids as drugs is reviewed. Delta1-Tetrahydrocannabinol (delta1-THC) is mainly investigated as a potential drug against glaucoma and asthma, and as an antiemetic agent in cancer chemotherapy. Cannabidiol is being tried in the clinic against epilepsy and as a hypnotic. Numerous synthetic cannabinoids are currently being investigated as analgetics and as sedative-relaxants.
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000932:Antiemetics; D001249:Asthma / Q000188:drug therapy; D002185:Cannabidiol / Q000627:therapeutic use; D002186:Cannabinoids / Q000627:therapeutic use; D002188:Cannabis; D013759:Dronabinol / Q000627:therapeutic use / Q000633:toxicity; D004827:Epilepsy / Q000188:drug therapy; D005901:Glaucoma / Q000188:drug therapy; D049690:History, Ancient; D049691:History, Medieval; D049711:History, Modern 1601-; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008514:Medicine, Arabic; D008518:Medicine, East Asian Traditional; D008517:Phytotherapy; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000932:Antiemetics; D002186:Cannabinoids; D002185:Cannabidiol; D013759:Dronabinol